EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Pyrrolone‐Fused Benzosuberene MK2 Inhibitors as Promising Therapeutic Agents for HNSCC: In Vitro Efficacy, In‐Vivo Safety, and Pharmacokinetic Profiling

Prince Anand iD, Jyoti Chhimwal iD, Sumit Dhiman, Yamini iD, Vikram Patial iD, Pralay Das iD, Zabeer Ahmed iD, Utpal Nandi iD, Mahvash Tavassoli iD, Yogendra Padwad iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Prince Anand und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), …. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Protein Serine-Threonine Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: This work was supported by the Council of Scientific and Industrial Research, India, and Newton-Bhabha PhD Placement Programme fellowship., Newton Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MAPKAPK2/MK2 is well implicated in the progression of Head and Neck Squamous Cell Carcinoma (HNSCC), and potent MK2‐inhibitors are required to suppress its activity. Several MK2‐inhibitors have been developed in recent years to combat its effects on cancer. However, inadequate solubility, insufficient cellular permeability, systemic toxicity‐mediated side effects, and low bioavailability have severely impeded the advancement of MK2‐inhibitors to clinical trials. This void necessitates research to develop less toxic and more bioavailable potent MK2‐inhibitors in HNSCC. In the present article, we have evaluated the in‐vitro efficacy, in‐vivo single‐dose acute toxicity, and in‐vivo pharmacokinetic profiling of recently developed PfBS (pyrrolone‐fused benzosuberene) MK2‐inhibitor analogues against HNSCC. The PfBS MK2 inhibitor analogues impeded HPV+ and HPV‐ HNSCC cell proliferation and two‐dimensional migration. Moreover, MK2‐inhibitors lowered HNSCC cell clonogenic survival in a dose‐dependent manner, significantly enhancing radiation‐induced cell death via exerting radio‐sensitization effects. Furthermore, γ‐H2AX immunostaining revealed that PfBS analogues impaired DNA damage repair in HNSCC cells exposed to gamma radiation. In mice, PfBS MK2 inhibitors at 300 mg/kg were well‐tolerated without any lethal effects. Pharmacokinetic studies showed that PfBS analogues exhibited rapid absorption (Tmax), adequate plasma concentration above the micromolar level (C0 or Cmax), limited tissue distribution (Vd), and faster elimination from the body (Cl). Overall, this study summarizes in‐vitro efficacy, safety, and pharmacokinetics of developed MK2‐inhibitors and opens doors for pharmacodynamics and mechanism of action study of most effective leads in HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckProtein Serine-Threonine KinasesAntineoplastic AgentsIntracellular Signaling Peptides and ProteinsPyrrolesProtein Kinase InhibitorsAnimalsHumansCell Line, TumorMiceCell ProliferationMaleMice, NudeFemaleXenograft Model Antitumor AssaysCell MovementMAP-Kinase-Activated Kinase 2

Stichwörter der Autor:innen

HNSCCMK2 inhibitoracute toxicityanticancerirradiationpharmacokinetics

Substanzen

Protein Serine-Threonine KinasesAntineoplastic AgentsIntracellular Signaling Peptides and ProteinsPyrrolesProtein Kinase InhibitorsMAP-Kinase-Activated Kinase 2

Autor:innen und Institutionen

  • Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, Himachal Pradesh, India.
  • Centre for Host-Microbiome Interactions, King's College London, London, London, United Kingdom.
  • Academy of Scientific and Innovative Research, AcSIR, Ghaziabad, Uttar Pradesh, India.
  • Pharmacology Division, CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu, Jammu & Kashmir, India.
  • Chemical Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur, Himachal Pradesh, India.
  • Chemical Sciences, Unified Academic Campus, Bose Institute, Kolkata, West Bengal, India.

ORCID-Profile: Prince Anand, Jyoti Chhimwal, Yamini, Vikram Patial, Pralay Das, Zabeer Ahmed, Utpal Nandi, Mahvash Tavassoli, Yogendra Padwad

Förderung

  • This work was supported by the Council of Scientific and Industrial Research, India, and Newton-Bhabha PhD Placement Programme fellowship.
  • Newton Fund

Zitieren

APA

Anand, P., Chhimwal, J., Dhiman, S., Yamini, Patial, V., Das, P., Ahmed, Z., Nandi, U., Tavassoli, M., & Padwad, Y. (2025). Evaluation of Pyrrolone‐Fused Benzosuberene MK2 Inhibitors as Promising Therapeutic Agents for HNSCC: In Vitro Efficacy, In‐Vivo Safety, and Pharmacokinetic Profiling. Drug Development Research. https://doi.org/10.1002/ddr.70062

Vancouver

Anand P, Chhimwal J, Dhiman S, Yamini, Patial V, Das P, et al. Evaluation of Pyrrolone‐Fused Benzosuberene MK2 Inhibitors as Promising Therapeutic Agents for HNSCC: In Vitro Efficacy, In‐Vivo Safety, and Pharmacokinetic Profiling. Drug Development Research. 2025. doi:10.1002/ddr.70062

BibTeX
@article{Anand2025,
  author = {Anand, Prince and Chhimwal, Jyoti and Dhiman, Sumit and Yamini and Patial, Vikram and Das, Pralay and Ahmed, Zabeer and Nandi, Utpal and Tavassoli, Mahvash and Padwad, Yogendra},
  title = {Evaluation of Pyrrolone‐Fused Benzosuberene MK2 Inhibitors as Promising Therapeutic Agents for HNSCC: In Vitro Efficacy, In‐Vivo Safety, and Pharmacokinetic Profiling},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70062}
}
Kostenlos starten →